Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies-Reference-Cited by-同舟云学术

Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies

Published:2017-05 Issue:5 Volume:20 Page:589-596
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Wei James C.-C.¹^ORCID,Baeten Dominique²,Sieper Joachim³,Deodhar Atul⁴,Bhosekar Vaishali⁵,Martin Ruvie⁶,Porter Brian⁶

Affiliation:

1. Division of Allergy, Immunology and Rheumatology; Chung Shan Medical University Hospital; Institute of Medicine; Chung Shan Medical University; Graduate Institute of Integrated Medicine; China Medical University; Taichung Taiwan

2. Academic Medical Centre; Amsterdam The Netherlands

3. Charité University Medicine Berlin; Berlin Germany

4. Oregon Health & Science University; Portland Oregon USA

5. Novartis Healthcare Pvt. Ltd.; Hyderabad India

6. Novartis Pharmaceuticals Corporation; East Hanover New Hampshire USA

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1756-185X.13094/fullpdf

Reference26 articles.

1. Ankylosing spondylitis;Braun;Lancet,2007

2. Global prevalence of ankylosing spondylitis;Dean;Rheumatology (Oxford),2014

3. Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis;Liu;Int J Clin Exp Med,2015

5. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis;Braun;Ann Rheum Dis,2011

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamics of T-cell receptor repertoire in patients with ankylosing spondylitis after biologic therapy;International Immunopharmacology;2024-01

2. Role of Th17 and IL-17 Cytokines on Inflammatory and Auto-immune Diseases;Current Pharmaceutical Design;2023-07

3. Ankylosing spondylitis shares a common therapeutic target with breast cancer;International Journal of Rheumatic Diseases;2023-03-06

4. Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials;Current Opinion in Pharmacology;2022-12

5. Propensity-matched Comparison Between Chronic Nonspecific Low Back Pain and Axial Spondyloarthritis: Impact on patient-perceived Quality of Life;Spine;2022-10-17